Around the world, patients with unmet medical needs are frequently driven to seek access to medicines outside the clinical trial and commercial setting. Idis is the leading expert in developing, implementing and managing global Managed Access Programs by which pharmaceutical and biotechnology companies and healthcare providers can respond to the needs of these patients.
Idis has 25 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from virtually every therapeutic category, impacting the lives of hundreds of thousands of patients. Around the world, a variety of terms are used to describe these programs including “expanded access”, “named patient”, “ATU”, “compassionate use”, and “early access”.
Idis leverages decades of experience, regulatory insight, and a thorough understanding of local and global requirements to create access to medicines at every stage of a product’s lifecycle from pre-approval to market exit, and in times of unexpected production shortages.
Idis is internationally headquartered in the United Kingdom, with US headquarters in Princeton, New Jersey .
Idis Partner for Life™
Specialties
Managed Access Program Development, Drug Shortages, Established Brands Management, Named Patient Program Development, Drug Discontinuation Management, Expanded Access Program Development
Idis Activity on LinkedIn
-
-
Idis has a new Medical Information Specialist
Syed Ziyad A. is now Medical Information Specialist
-
Idis has a new International Costumer Services
Marga Mas is now International Costumer Services, was Medical sales representative at Italfarmaco
-
Idis has a new UK Retail Director
Victoria Buyer is now UK Retail Director


